Active ingredient: Bumetanide 

 

Form/Route: Tablet/Oral 

 

Recommended studies: 2 studies 

 

1. Type of study: Fasting 


Design: Single-dose, two-way crossover in vivo 

Strength: 2 mg 

Subjects: Healthy males and non-pregnant females, general population. 

Additional comments: 

______________________________________________________________________________ 

 

2. Type of study: Fed 


Design: Single-dose, two-way crossover in vivo 

Strength: 2 mg 

Subjects: Healthy males and non-pregnant females, general population. 

Additional Comments: 

______________________________________________________________________________ 

 

Analytes to measure (in appropriate biological fluid): Bumetanide in plasma 

 

Bioequivalence based on (90% CI): Bumetanide 

 

Waiver request of in vivo testing: 0.5 mg and 1 mg based on (i) acceptable bioequivalence 
studies on the 2 mg strength, (ii) acceptable in vitro dissolution testing of all strengths, and (iii) 
proportional similarity of the formulations across all strengths. 

 

Dissolution test method and sampling times: 

Please note that a Dissolution Methods Database is available to the public at the OGD website 
at http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the dissolution 
information for this product at this website. Please conduct comparative dissolution testing on 12 
dosage units each of all strengths of the test and reference products. Specifications will be 
determined upon review of the application. 

 


